IMU Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 14.40%

Insider Buying (Last 12 Months): A$0.00

Insider Selling (Last 12 Months): A$0.00

Imugene Insider Trading History Chart

Imugene Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 05/13/2020 01:00 AM ET

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Imugene Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/1/2024	Paul Hopper	Insider	Issued	1,381,422	A$0.02	A$20,721.33
1/12/2024	Lesley Russell	Insider	Issued	1,000,000	A$0.12	A$120,000.00
10/5/2023	Paul Hopper	Insider	Issued	535,714	A$0.05	A$24,107.13
10/3/2023	Jens Eckstein	Insider	Issued	238,095	A$0.08	A$19,999.98
12/15/2022	Jakob Dupont	Insider	Issued	2,100,000	A$0.18	A$367,500.00
11/4/2022	Charles Walker	Insider	Buy	25,000,000	A$0.04	A$1,075,000.00
6/9/2022	Charles Walker	Insider	Buy	128,000	A$0.16	A$19,840.00
6/7/2022	Lesley Russell	Insider	Buy	10,000,000	A$0.05	A$450,000.00
2/7/2022	Jens Eckstein	Insider	Sell	2,100,000	A$0.30	A$630,000.00
12/13/2021	Paul Hopper	Insider	Sell	1,248,900	A$0.49	A$611,961.00
10/22/2021	Paul Hopper	Insider	Issued	1,248,600	A$0.02	A$18,729.00
7/1/2021	Lesley Russell	Insider	Buy	15,000,000	A$0.04	A$630,000.00
5/28/2021	Leslie (Mi Ok) Chong	Insider	Exercise	13,844,444	A$0.05	A$622,999.98
5/25/2021	Leslie (Mi Ok) Chong	Insider	Sell	4,485,889	A$0.37	A$1,646,321.26
5/21/2021	Charles Walker	Insider	Sell	3,500,000	A$0.35	A$1,235,500.00

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

SEC Filings (Institutional Ownership Changes) for Imugene (ASX:IMU)

6.16% of Imugene stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

12,699,963 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

3.03%

Beta

3.23

Who are the company insiders with the largest holdings of Imugene?: Imugene's top insider investors include:
Charles Walker (Insider)
Jakob Dupont (Insider)
Jens Eckstein (Insider)
Lesley Russell (Insider)
Paul Hopper (Insider)
Learn More about top insider investors at Imugene.